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Endocannabinoids are amides and esters of long chain
polyunsaturated fatty acids, which act as mediators in brain
and peripheral tissues through the binding to cannabinoid
receptors. Anandamide (N-arachidonylethanolamine, AEA)
is a major endocannabinoid, showing cardiovascular activity
[1] by induction of vasorelaxation [2]. Although AEA has
been described as an endothelium-derived hyperpolarizing fac-
tor (EDHF), this hypothesis was debated and recent data
suggest that EDHF is instead a cytochrome P450-metabolite
[3]. Whether or not an EDHF, AEA is likely to play an
important role in the control of vascular tone, as supported
also by the observation that both rat endothelial cells and
macrophages can release it [4].
We found and published in this journal [5] that AEA (91.2
mM) activates human platelets by a cannabinoid receptor-in-
dependent mechanism, which involves a rise in intracellular
calcium and does not depend on the arachidonate cascade. In
the same paper we showed that human platelets have the bio-
chemical machinery to degrade AEA, i.e. a high a⁄nity trans-
porter and a fatty acid amide hydrolase (FAAH). Afterwards,
these data have been largely con¢rmed by Braud et al. [6],
who found that AEA in rabbit platelets was active at physio-
logical concentrations (910 WM) when used in combination
with CaCl2 and ¢brinogen. These authors attributed the ag-
gregating e¡ect of AEA to its cleavage into arachidonic acid
by an AEA-degrading enzyme [6]. At any extent, these data
suggest that AEA is an unlikely physiological agonist of plate-
lets, but it can rather act in vivo as a co-agonist in combina-
tion with other ‘classical’ aggregating molecules such as ara-
chidonic acid, ¢brinogen or thrombin [5,6]. However, the role
of endocannabinoids in the cross-talk between platelets and
endothelium, which might be crucial in thrombosis, still
awaits clari¢cation.
Platelet activation by AEA appears of interest also because
it can be released from endothelial cells and macrophages in
rats [4]. This suggests an interplay between di¡erent blood
cells in regulating the peripheral endocannabinoid system,
hence the cardiovascular activities of these newly discovered
lipid mediators [1^4]. In keeping with this concept, we showed
that peripheral human cells such as lymphoma (U937) cells
[7], lymphocytes [8], endothelial (HUVEC) cells [9] and mas-
tocytes (HMC-1) [10] take up AEA and degrade it through
FAAH. The apparent kinetic constants of FAAH in human
blood cells (Table 1) suggest that a similar enzyme is ex-
pressed to di¡erent extents, showing similar Km but di¡erent
Vmax values (Table 1). Finally, it should be stressed that plate-
let activation is paralleled by a decrease in nitric oxide, which
stimulates AEA uptake by human cells [7^10]. Therefore,
platelets can a¡ect endocannabinoid degradation by the
neighboring blood cells, contributing to the control of these
compounds.
References
[1] Wagner, J.A., Varga, K., Ja'rai, Z. and Kunos, G. (1999) Hyper-
tension 33, 429^434.
[2] Ja¤rai, Z., Wagner, J., Varga, K., Lake, K.D., Compton, D.R.,
Martin, B.R., Zimmer, A.M., Bonner, T.I., Buckley, N.E., Me-
zey, E., Razdan, R.K., Zimmer, A. and Kunos, G. (1999) Proc.
Natl. Acad. Sci. USA 96, 14136^14141.
[3] Fisslthaler, B., Popp, R., Kiss, L., Potente, M., Harder, D.R.,
Fleming, I. and Busse, R. (1999) Nature 401, 493^497.
[4] Varga, K., Wagner, J.A., Bridgen, D.T. and Kunos, G. (1998)
FASEB J. 12, 1035^1044.
[5] Maccarrone, M., Bari, M., Menichelli, A., Del Principe, D. and
Finazzi-Agro' , A. (1999) FEBS Lett. 447, 277^282.
[6] Braud, S., Bon, C., Touqui, L. and Mounier, C. (2000) FEBS
Lett. 471, 12^16.
[7] Maccarrone, M., van der Stelt, M., Rossi, A., Veldink, G.A.,
Vliegenthart, J.F.G. and Finazzi-Agro' , A. (1998) J. Biol. Chem.
273, 32332^32339.
[8] Maccarrone, M., Valensise, H., Bari, M., Lazzarin, N., Romani-
ni, C. and Finazzi-Agro' , A. (2000) Lancet 355, 1326^1329.
[9] Maccarrone, M., Bari, M., Lorenzon, T., Bisogno, T., Di Marzo,
V. and Finazzi-Agro', A. (2000) J. Biol. Chem. 275, 13484^13492.
[10] Maccarrone, M., Fiorucci, L., Erba, F., Bari, M., Finazzi-Agro',
A. and Ascoli, F. (2000) FEBS Lett. 468, 176^180.
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 2 0 8 0 - 9
Table 1
Kinetic parameters of FAAH activity in human peripheral cells
Human cells Km (WM) Vmax (pmol min31 mg protein31) Reference
Platelets 10 þ 1.0 270 þ 30 [5]
Lymphoma cells (U937) 6.5 þ 0.6 520 þ 50 [7]
Lymphocytes 8.0 þ 1.0 187 þ 20 [8]
Endothelial cells (HUVEC) 7.0 þ 0.7 25 þ 3 [9]
Mast cells (HMC-1) 5.0 þ 0.5 160 þ 15 [10]
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